A prospective phase I/II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix-acute toxicity and biomarker response analysis

P Chan, C Doll, A Oza, M Pintilie, W Levin, L Manchul… - 2003 - osti.gov
To evaluate the toxicity and biomarker response of celecoxib (C) as a biologic modifier in
combination with definitive chemoradiotherapy (CRT) in women with cervix cancer. Fifteen …
相关文章

A prospective phase I/II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix-acute toxicity and biomarker response analysis

P Chan, C Doll, A Oza, M Pintilie, W Levin, L Manchul… - inis.iaea.org
[en] To evaluate the toxicity and biomarker response of celecoxib (C) as a biologic modifier
in combination with definitive chemoradiotherapy (CRT) in women with cervix cancer …